Zja­wi­ska im­mu­no­lo­gicz­ne pro­wa­dzą­ce do pa­to­lo­gii fil­mu łzo­we­go. Czy cy­klo­spo­ry­na bę­dzie prze­ło­mem w le­cze­niu ze­spo­łu Sjögre­na? Do­nie­sie­nie wstęp­ne

Purpose
The purpose of this study is to examine the new way in the casual treatment, resulting in the normalization of immunological processes on the ocular surface.

Material and methods
5 patients (4 women and 1 men with mean age of 55,5 years, range 45 to 59 years) with Sjögren’s syndrome – type dry eye, were included in the study. Patients received topically 0,05% cyclosporine, ophthalmic emulsion twice a day for a 6 months. The severity of patients complaints was evaluated according to the Dr. Mann Pharma / Bausch & Lomb’s record.

Results
Schirmer test II values, and lyzamine green staining scores, were evaluated priori to treatment and 6 months after the start. At the beginning of the study (day 0) the Schirmer test II values ranged from 1 to 5 mm (mean – 2,2 mm). Break-up-time ranged from 3 to 6 sec (mean – 4,8 sec). In all of 5 cases lyzamine green staining scores were 9. On month 6th, all of 5 patients had significant differences, compared to their baseline measurements in term of above mentioned parameters. The Schirmer test II values ranged from 8 to 12 mm (mean – 10,3 mm). Break-up-time ranged from 9 to 13 sec (mean – 11,2 sec), lyzamine green staining scores ranged from 2 to 3 points (mean – 2,7).

Conclusions
0,05% cyclosporine, ophthalmic emulsion had a beneficial effect both on the subjective and objective clinical parameters of dry eye patients. The final conclusions must be supported by more cases.